# LRRK2 Mutation and Parkinson's Disease

> **NCT01424475** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 5 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **GENETIC:** Healthy
- **GENETIC:** PKD Patients

## Key facts

- **NCT ID:** NCT01424475
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-08-11
- **Primary completion:** 2015-01-12
- **Final completion:** 2015-01-12
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Following extensive efforts to increase recruitment, it will not be possible to complete the study protocol within a reasonable time
- **Last updated:** 2017-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01424475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01424475, "LRRK2 Mutation and Parkinson's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01424475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*